89026-79-9

Usage

Uses

Used in Pharmaceutical Research and Development:
(6-Bromo-pyridin-2-yl)-methyl-amine is used as a key intermediate in the synthesis of pharmaceuticals for its potential to contribute to the development of biologically active molecules. Its unique structural features make it a valuable component in creating new drug candidates that can address unmet medical needs.
Used in Organic Synthesis:
In the field of organic synthesis, (6-Bromo-pyridin-2-yl)-methyl-amine is used as a building block for constructing complex organic molecules. Its bromo substituent and aminoethyl group provide opportunities for further functionalization and the creation of diverse chemical entities.
Used in Heterocyclic Compound Synthesis:
(6-Bromo-pyridin-2-yl)-methyl-amine is utilized as a reagent in the synthesis of heterocyclic compounds, which are an important class of compounds with applications in various fields, including pharmaceuticals, agrochemicals, and materials science. Its ability to participate in a range of reactions makes it a versatile component in the synthesis of these compounds.
Used in Chemical Reactions as a Reagent:
As a reagent in chemical reactions, (6-Bromo-pyridin-2-yl)-methyl-amine aids in various transformation processes, facilitating the formation of desired products in organic chemistry. Its presence can influence the course of reactions and improve the efficiency of synthetic routes.

Upstream product

• 19798-81-3 2-Amino-6-bromopyridine 
• 13061-96-6 dihydroxy-methyl-borane 
• 626-05-1 2,6-Dibromopyridine 
• 593-51-1 methylamine hydrochloride 
• 74-89-5 methylamine 
• 817618-19-2 tert-butyl (6-bromopyridin-2-yl)(methyl)carbamate 
• 74-88-4 methyl iodide 

Downstream Products

• 801240-09-5 2-(5-tert-butoxycarbonylamino-pentyloxy)-4-(6-methylamino-pyridin-2-ylethynyl)-benzoic acid methyl ester 
• 801239-91-8 2-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethoxy}-4-(6-methylamino-pyridin-2-ylethynyl)-benzoic acid methyl ester 
• 801240-19-7 4-[2-(6-methylamino-pyridin-2-yl)-ethyl]-benzoic acid 
• 801239-95-2 2-benzenesulfonylamino-3-{4-[2-(6-methylamino-pyridin-2-yl)-ethyl]-benzoylamino}-propionic acid tert-butyl ester 
• 801239-52-1 2-(benzenesulfonyl-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethyl}-amino)-3-{4-[2-(6-methylamino-pyridin-2-yl)-ethyl]-benzoylamino}-propionic acid tert-butyl ester 
• 801239-54-3 2-(4-{3-[2-(2-tert-butoxycarbonylamino-ethoxy)-ethoxy]-propyl}-benzenesulfonylamino)-3-{4-[2-(6-methylamino-pyridin-2-yl)-ethyl]-benzoylamino}-propionic acid tert-butyl ester 
• 935397-21-0 ethyl (Z)-2-ethoxy-3-[4-(6-methylaminopyrid-2-yl)phenyl]acrylate 
• 4597-87-9 2-(N-methylamino)pyridine 
• 1220596-13-3 benzyl 2-(6-(methylamino)pyridin-2-yl)ethylcarbamate 
• 1589588-13-5 C₁₇H₁₆BrN₅ 
• 1589588-15-7 C₁₈H₁₈BrN₅O 
• 1589588-05-5 C₁₈H₁₈BrN₅ 
• 1589588-07-7 C₁₈H₁₅BrN₆ 
• 1589588-32-8 C₅₁H₄₅N₁₅ 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

BENZOSULFONYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

A compound of Formula I useful as an emitter in OLED is disclosed.

Phosphonic acid derivatives and application thereof

The invention belongs to the field of medical chemistry, relates to phosphonic acid derivatives for treating virus infectious diseases and an application thereof, and in particular, relates to the compounds represented by the formula (I) or isomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, a preparation method thereof, pharmaceutical compositions containing the compounds and an application of the compounds or the compositions in preparation of drugs for treating the virus infection diseases.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: Structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)

The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [3H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emaxof the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS

The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1.

Convenient synthesis of aminopyridinecarboxylic acids

6-(Alkylamino)pyridine-2-carboxylic acids and 5-(alkylamino)pyridine-3- carboxylic acids were conveniently synthesized from dibromopyridine in satisfactory yields.

Synthesis of (NH)m(NMe)4-m-bridged calix[4]pyridines and the effect of NH bridge on structure and properties

(Chemical Equation Presented) The (NH)m(NMe)4-m- bridged calix[4]pyridines (m = 1-4) 19-23 were synthesized in excellent yields from deprotection of N-allyl groups of (NAllyl)m(NMe) 4-m-bridged calix[4]pyridine derivatives 8 and 15-18, which were prepared in moderate yields by macrocyclic 2+2 and 1+3 coupling reactions between simple diamino- and dibromo-substituted fragments. In the solid state, (NH)m(NMe)4-m-bridged calix[4]pyridines adopted different 1,3-alternate conformations due to mainly the formation of varied conjugation systems of bridging NH units with their neighboring pyridines. In solution, all (NH)m(NMe)4-m-bridged calix[4]pyridines were very fluxional and the rates of interconversion of various conformational structures were very rapid relative to the NMR time scale. While (NH)4-bridged calix[4]pyridine 23 formed the strongest conjugation system, (NH) 2(NMe)2-bridged calix[4]pyridine 21 acted as a selective fluorescence probe in the recognition of zinc(II) ion in solution with the dramatic enhancement of fluorescence intensity.

NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS

Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): are formulated into pharmaceutical compositions useful in human or veterinary medicine, or alternatively, in cosmetic compositions.

3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES

The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.